Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8023836 | PMC |
| http://dx.doi.org/10.1093/jnci/djaa125 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Advanced-stage duodenal cancer in pregnancy.
BMJ Case Rep
January 2025
Maternal Fetal Medicine, University of Louisville Hospital, Louisville, Kentucky, USA.
This is a case report of a pregnant patient diagnosed with advanced-stage duodenal cancer in the second trimester. To the author's knowledge, there are no studies that describe the management of advanced duodenal cancer during pregnancy and this case highlights the importance of creating a multidisciplinary team and incorporating shared decision-making when discussing diagnostic workup and treatment options, including the use of cytotoxic therapy during pregnancy, with patients. This study will also discuss maternal and fetal outcomes after the administration of FOLFOX (leucovorin, fluorouracil and oxaliplatin) chemotherapy during the second trimester.
View Article and Find Full Text PDFDietary Supplements for Weight Loss and Drug Interactions.
Pharmaceuticals (Basel)
December 2024
Department of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of Granada, 18071 Granada, Spain.
Food supplements are used for a variety of purposes, one of which is weight reduction. As excess weight is a long-term condition, some supplements are expected to be used for long periods of time. The long-term use of these dietary supplements makes it highly likely that they will be combined with medications, increasing the risk of food supplement-drug interactions, which are not always known or disclosed, and can lead to serious health problems, as has been observed.
View Article and Find Full Text PDFCost-effectiveness analysis of first-line combination chemotherapy regimens for metastatic pancreatic cancer and evidence-based pricing strategy of liposomal irinotecan in China.
Front Pharmacol
December 2024
Department of Pharmacy, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Hunan Cancer Hospital, Changsha, China.
Background: The phase III NAPOLI-3 trial, which upgraded FOLFIRINOX (leucovorin, fluorouracil, irinotecan and oxaliplatin) to NALIRIFOX (liposomal irinotecan, oxaliplatin, leucovorin, and fluorouracil), demonstrated the superiority of NALIRIFOX over GEMNABP (gemcitabine and nab-paclitaxel) as the first-line treatment for metastatic pancreatic ductal adenocarcinoma. The purpose of this study was to assess the cost-effectiveness of NALIRIFOX, FOLFIRINOX, and GEMNABP, and to simulate the price of liposomal irinotecan at which NALIRIFOX could achieve cost-effectiveness.
Methods: A partitioned survival model was performed to evaluate the cost-effectiveness of NALIRIFOX, FOLFIRINOX and GEMNABP from the perspective of the Chinese healthcare system.
Exploring the drug delivery capabilities of NbC MXene functionalized with oxygen and fluorine: A DFT study.
J Mol Graph Model
January 2025
School of Materials Science and Engineering, Yancheng Institute of Technology, Yancheng, 224051, China. Electronic address:
MXenes quantum dots (QDs), including NbC, NbCO, and NbCF, are emerging materials with exceptional structural, electronic, and optical properties, making them highly suitable for biomedical applications. This study investigates the structural optimization, stability, electronic properties, and drug-loading potential of these QDs using fluorouracil (Flu) as a model drug. Structural analyses show that the functionalization of NbC with O and F atoms enhances stability, with binding energies (BEs) of 7.
View Article and Find Full Text PDFAnlotinib in combination with metronomic chemotherapy in HER2-negative metastatic breast cancer: an observational and retrospective study.
BMC Cancer
January 2025
Department of Medical Oncology, National Cancer Center, National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No.17 PanjiayuanNanli, Chaoyang District, Beijing, 100021, China.
Anti-angiogenesis offers an important treatment strategy for metastatic breast cancer (MBC). Metronomic chemotherapy (MCT) provides antiangiogenic effects without increased toxicities, making it good partner for antiangiogenic therapy. We conducted the present retrospective study to evaluate the efficacy and safety of anlotinib plus MCT for HER2 negative MBC.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!